Optimizing the Assessment of Refractive Outcomes After Cataract Surgery
Primary Purpose
Cataract
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Manifest refraction
ACRYSOF® IQ Monofocal IOL Model SN60WF
Topcon® KR-1W Wave-Front Analyzer
Sponsored by
About this trial
This is an interventional other trial for Cataract focused on measuring Intraocular Lens (IOL)
Eligibility Criteria
Inclusion Criteria:
- Able to understand and sign an Ethics Committee/Institutional Review Board approved Informed Consent;
- Willing and able to attend all scheduled study visits as required per protocol;
- Diagnosed with cataract in one or both eyes;
- Planned cataract removal by phacoemulsification with implantation of a monofocal IOL; laser refractive procedures for incisions (primary and sideport), capsulorhexis and lens fragmentation are allowed;
- Preoperative keratometric astigmatism ≤ 1.0 diopter (D);
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
- Women of childbearing potential, pregnant, or breast-feeding;
- History of ocular pathology, ocular inflammation, or ocular conditions, as specified in the protocol;
- Previous intraocular or corneal surgery;
- Use of systemic medications that, in the opinion of the Investigator, may confound the outcome or increase the risk of complications to the subject;
- Any medical condition that, in the opinion of the Investigator, may confound the results of this study, prohibit the completion of the study assessments, or increase the risk for the subject;
- Other protocol-defined exclusion criteria may apply.
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Manifest refraction
Arm Description
Manifest refraction performed by autorefraction (automated) and manual procedures (standard). Subject implanted with ACRYSOF® IQ Monofocal IOL Model SN60WF. Autorefraction performed by Topcon® KR-1W Wave-Front Analyzer.
Outcomes
Primary Outcome Measures
IOL A-constant at 3 Months at Each Site
The A-constant, is a type of IOL constant, that accounts for clinical variables that may affect the refractive outcome (e.g. patient factors, biometry method). It relates the power of the IOL to axial length and corneal measurements. It is specific to the design of the IOL, style, and placement within the eye. The optimization of the A-constant is fundamental to achieving the targeted refractive outcomes, offset any observed error and for ensuring high patient satisfaction following cataract surgery. Since errors/noise from refraction plays a significant role in A-constant optimization, it is important to determine if an automated method has any advantages over conventional manifest refraction. A-constants based on autorefraction and manifest refraction for the study eye are compared for each subject. The mean difference between the two methods cannot be greater than 0.15 D at each of the three study centers for the methods to be considered equivalent.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02842151
Brief Title
Optimizing the Assessment of Refractive Outcomes After Cataract Surgery
Official Title
Optimizing the Assessment of Refractive Outcomes After Cataract Surgery and Implantation of a Monofocal IOL
Study Type
Interventional
2. Study Status
Record Verification Date
November 2018
Overall Recruitment Status
Completed
Study Start Date
September 21, 2016 (Actual)
Primary Completion Date
November 16, 2017 (Actual)
Study Completion Date
November 16, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alcon Research
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate current available assessments (automated vs. manual) with which manifest refraction data and biometric variables are obtained to understand if data from an automated refractor can be utilized to optimize the A-constant as well as manual subjective refraction (ie, to a clinically insignificant difference). The A-constant is the calculated number that helps the surgeon determine which IOL should be implanted in the eye during cataract surgery.
Detailed Description
Subjects will be implanted with ACRYSOF® IQ Monofocal IOL Model SN60WF. Standard clinical practice will be followed for pre-operative testing, IOL power estimation and IOL implantation. Only one eye will be enrolled in the study per surgeon determination. The eye will undergo both an automated and manual manifest refraction assessment at 3 months postoperative.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cataract
Keywords
Intraocular Lens (IOL)
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Outcomes Assessor
Allocation
N/A
Enrollment
162 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Manifest refraction
Arm Type
Other
Arm Description
Manifest refraction performed by autorefraction (automated) and manual procedures (standard). Subject implanted with ACRYSOF® IQ Monofocal IOL Model SN60WF. Autorefraction performed by Topcon® KR-1W Wave-Front Analyzer.
Intervention Type
Procedure
Intervention Name(s)
Manifest refraction
Intervention Description
Manifest refraction performed by autorefraction (automated) and manual procedures (standard)
Intervention Type
Device
Intervention Name(s)
ACRYSOF® IQ Monofocal IOL Model SN60WF
Intervention Description
Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
Intervention Type
Device
Intervention Name(s)
Topcon® KR-1W Wave-Front Analyzer
Intervention Description
Wavefront and topography system used to obtain autorefraction data
Primary Outcome Measure Information:
Title
IOL A-constant at 3 Months at Each Site
Description
The A-constant, is a type of IOL constant, that accounts for clinical variables that may affect the refractive outcome (e.g. patient factors, biometry method). It relates the power of the IOL to axial length and corneal measurements. It is specific to the design of the IOL, style, and placement within the eye. The optimization of the A-constant is fundamental to achieving the targeted refractive outcomes, offset any observed error and for ensuring high patient satisfaction following cataract surgery. Since errors/noise from refraction plays a significant role in A-constant optimization, it is important to determine if an automated method has any advantages over conventional manifest refraction. A-constants based on autorefraction and manifest refraction for the study eye are compared for each subject. The mean difference between the two methods cannot be greater than 0.15 D at each of the three study centers for the methods to be considered equivalent.
Time Frame
Month 3 (Day 80-100) Post Study Eye Implantation
10. Eligibility
Sex
All
Minimum Age & Unit of Time
22 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Able to understand and sign an Ethics Committee/Institutional Review Board approved Informed Consent;
Willing and able to attend all scheduled study visits as required per protocol;
Diagnosed with cataract in one or both eyes;
Planned cataract removal by phacoemulsification with implantation of a monofocal IOL; laser refractive procedures for incisions (primary and sideport), capsulorhexis and lens fragmentation are allowed;
Preoperative keratometric astigmatism ≤ 1.0 diopter (D);
Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
Women of childbearing potential, pregnant, or breast-feeding;
History of ocular pathology, ocular inflammation, or ocular conditions, as specified in the protocol;
Previous intraocular or corneal surgery;
Use of systemic medications that, in the opinion of the Investigator, may confound the outcome or increase the risk of complications to the subject;
Any medical condition that, in the opinion of the Investigator, may confound the results of this study, prohibit the completion of the study assessments, or increase the risk for the subject;
Other protocol-defined exclusion criteria may apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alcon, A Novartis Division
Organizational Affiliation
Alcon, A Novartis Division
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Optimizing the Assessment of Refractive Outcomes After Cataract Surgery
We'll reach out to this number within 24 hrs